Rigel Pharmaceuticals RIGL Proceeds from Maturities, Prepayments and Calls of Short-Term Investments
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments?
- Rigel Pharmaceuticals (RIGL) reported proceeds from maturities, prepayments and calls of short-term investments of $15.95M in Q1 2026.
- How has Rigel Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments changed year-over-year?
- Rigel Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments increased by 43.6% year-over-year, from $11.1M to $15.95M.
- What is the long-term trend for Rigel Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's proceeds from maturities, prepayments and calls of short-term investments has grown at a -0.4% compound annual growth rate (CAGR), from $62.05M to $61.13M.